Developer docs
API playgroundTry for free, no card

Search company profiles

Nanostics

Full company profile

uuid0002jxw

Namestring
Nanostics
Legal namestring
Nanostics Inc.
Websiteurl
nanosticsdx.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Nanostics Inc. (operating as Nanostics Precision Health) is a privately held Canadian diagnostic company headquartered in Edmonton, Alberta, that develops and commercializes the ClarityDX platform — an AI-driven blood-based diagnostic system for prostate cancer risk assessment. Its flagship product, ClarityDX Prostate, analyzes standard clinical inputs (age, total PSA, free PSA ratio, prostate volume, PI-RADS score, prior negative biopsy status, and DRE findings) through proprietary machine learning models to generate a risk score for aggressive prostate cancer (Grade Group ≥3). The platform offers four model variants (base, +DRE, +MRI, +DRE+MRI) that have demonstrated AUCs of 0.81–0.88 across multi-institutional validation and can reduce unnecessary biopsies by 47% while maintaining detection of over 94% of aggressive cancers. A complementary EV-Fingerprint test, which uses extracellular vesicle biomarkers analyzed via microflow cytometry combined with machine learning, is also in the company's pipeline.

Nanostics commercializes ClarityDX Prostate through a dual go-to-market approach: a direct-to-consumer e-commerce channel with provincial pricing ($300 CAD in Alberta, $500 CAD in British Columbia, undisclosed elsewhere), plus enterprise healthcare system partnerships anchored by a clinical laboratory relationship with Alberta Precision Laboratory. The test is currently available in six Canadian provinces (Alberta, British Columbia, Ontario, Quebec, Saskatchewan, and Yukon) and the company is pursuing FDA approval to enter the US market. The business is supported by grant and equity funding from Genome Canada, Genome Alberta, the University of Alberta Innovation Fund, NRC-IRAP, Alberta Innovates, Prostate Cancer Canada, Ride for Dad, and other regional partners, with the most recent disclosed round being a $2.79M Canadian Biotechnology Innovation and Commercialization Initiative round in June 2025.

The company operates with a small team of 1–10 employees led by CEO and founder Dr. John Lewis (Bird Dogs Chair of Translational Oncology at the University of Alberta), Co-Founder and COO Catalina Vasquez, CTO and Co-Founder Robert Paproski, CCO Colin Coros, and CSO Desmond Pink. The company originated from academic research at the University of Alberta and underwent a strategic pivot from its original nanotechnology focus to a machine learning diagnostic platform. Revenue is not publicly disclosed and the company remains in early commercialization, with growth signals concentrated in geographic expansion (FDA pathway), product extensions (EV-Fingerprint), and accumulating peer-reviewed scientific validation.

Short descriptiontext

Nanostics Precision Health is an Edmonton-based diagnostic company that develops and commercializes ClarityDX Prostate, an AI-driven blood test that generates risk scores for aggressive prostate cancer to help patients and clinicians decide whether a biopsy is needed. The company sells the test directly to consumers across six Canadian provinces and through healthcare system partners, and is pursuing FDA approval for US market entry.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEdmonton, Canada
HQ citystring
Edmonton
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prostate cancer diagnostics, blood-based biomarker assays, machine learning diagnostics, cancer risk prediction, clinical laboratory services
Industry4 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code4 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Testing Laboratories8734
  • Services-Commercial Physical & Biological Research8731
Product category
Cancer Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Test Sales
TypeOne Time License
Description

Revenue generated from direct sales of ClarityDX Prostate test to consumers and healthcare providers. Test is available for ordering online with pricing varying by province in Canada.

nanosticsdx.com
2Healthcare System Partnerships
TypeSubscription Recurring
Description

Revenue potential through reimbursement agreements with provincial healthcare systems and adoption into clinical workflows.

prnewswire.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
Pricing details6 tiers
1ClarityDX Prostate Test - Alberta
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$300.00 per test for Alberta residents

nanosticsdx.com
2ClarityDX Prostate Test - British Columbia
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$500.00 per test for British Columbia residents

nanosticsdx.com
3ClarityDX Prostate Test - Ontario
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Price not publicly disclosed

nanosticsdx.com
4ClarityDX Prostate Test - Quebec
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Price not publicly disclosed

nanosticsdx.com
5ClarityDX Prostate Test - Saskatchewan
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Price not publicly disclosed

nanosticsdx.com
6ClarityDX Prostate Test - Yukon
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Price not publicly disclosed

nanosticsdx.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1ClarityDX
Description

AI-powered diagnostic platform that analyzes clinical data to provide actionable decision support for next-step testing, applicable to a wide range of cancers and other diseases.

nanosticsdx.com
+1 more record
Core offering1 text field

Nanostics develops and sells ClarityDX Prostate, a blood-based diagnostic test that uses proprietary machine learning algorithms to generate a risk score for aggressive prostate cancer (Grade Group ≥3) from standard clinical inputs (age, PSA, free PSA ratio, DRE, MRI findings) and blood-based biomarkers. The test is offered in four model variants (base, +DRE, +MRI, +DRE+MRI) and is processed at Nanostics' accredited clinical laboratory in Edmonton, with results used by urologists and primary care physicians to inform prostate biopsy decisions and reduce unnecessary invasive procedures.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Reduces unnecessary biopsies by 47% while maintaining detection of over 94% of aggressive cancers
+4 more records
Product overview1 text field

Nanostics offers the ClarityDX platform, an AI-powered diagnostic system for prostate cancer risk assessment. The core product is ClarityDX Prostate, a blood-based test that analyzes clinical features and blood-based biomarkers using machine learning to generate risk scores for aggressive prostate cancer. The platform offers four model variants: the base ClarityDX Prostate model, plus optional modules for Digital Rectal Exam (DRE) data and/or MRI data. Regional variants are available across Canadian provinces (Alberta, British Columbia, Ontario, Quebec, Saskatchewan, Yukon) with varying pricing. The test is designed as an adjunctive tool for men with elevated PSA results to help determine whether a prostate biopsy is necessary.

Product and service4 records
1ClarityDX Prostate
CategoryCancer Diagnostics
Description

A blood-based diagnostic test that uses machine learning to analyze clinical features (age, total PSA, free PSA ratio, prostate volume from MRI, PI-RADS, prior negative biopsy status, DRE findings) and blood-based biomarkers to generate a calibrated risk score for aggressive prostate cancer (Grade Group ≥3). Designed as an adjunctive test for men with elevated PSA results to help determine whether a prostate biopsy is necessary; processed at Nanostics' accredited clinical laboratory in Edmonton. Achieves AUC of 0.81 in base form, with reductions of unnecessary biopsies by up to 47% while detecting over 94% of aggressive cancers.

2ClarityDX Prostate +DRE
CategoryCancer Diagnostics
Description

Extended ClarityDX Prostate model variant incorporating Digital Rectal Exam (DRE) data in addition to clinical features and blood biomarkers to predict aggressive prostate cancer. Achieves AUC of 0.82 in multi-institutional validation across six institutions in Canada, the United States, and Europe.

3ClarityDX Prostate +MRI
CategoryCancer Diagnostics
Description

Extended ClarityDX Prostate model variant incorporating MRI data (prostate volume and PI-RADS score) in addition to clinical features and blood biomarkers to predict aggressive prostate cancer. Achieves AUC of 0.87 without DRE and 0.88 with DRE in multi-institutional validation across six institutions in Canada, the United States, and Europe.

4ClarityDX Prostate +DRE +MRI
CategoryCancer Diagnostics
Description

Extended ClarityDX Prostate model variant incorporating both Digital Rectal Exam (DRE) and MRI data (prostate volume, PI-RADS score) in addition to clinical features and blood biomarkers to predict aggressive prostate cancer. The combined-input configuration reaches the highest AUC in the published multi-institutional validation across six institutions in Canada, the United States, and Europe.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical site for multi-institutional validation study of ClarityDX Prostate models. Provided patient data and clinical expertise for model development and validation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical site for multi-institutional validation study contributing patient cohorts and clinical data for model validation across six institutions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical site for multi-institutional validation study contributing patient data and urological expertise.

4Thomayer University Hospital
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical site in Prague, Czech Republic for multi-institutional validation study, providing diverse patient population for model validation.

nanosticsdx.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical site for multi-institutional validation study contributing patient data from urology practice.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical laboratory partner shown in company partnerships section, involved in processing ClarityDX Prostate tests in Alberta.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner organization supporting pharmaceutical innovation ecosystem in Alberta.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Impact fund supporting innovation and entrepreneurship in Edmonton/Alberta region.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Edmonton-based innovation ecosystem partner supporting startups and technology companies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

MDxHealth's SelectMDx is a urine-based molecular test that helps determine the risk of clinically significant prostate cancer prior to biopsy — directly competing with ClarityDX Prostate in the same urology decision-support workflow.

TypeDirect peer
Description

OPKO markets the 4Kscore test, a blood-based prostate cancer risk assessment that, like ClarityDX Prostate, aims to reduce unnecessary biopsies by stratifying risk of aggressive disease in men with elevated PSA.

TypeDirect peer
Description

Veracyte's Decipher Prostate Genomic Classifier is a tissue-based genomic test for risk stratification in prostate cancer, addressing the same biopsy/treatment decision points that ClarityDX Prostate targets upstream of biopsy.

TypeBroad incumbent
Description

Exact Sciences is a major oncology diagnostics company (Cologuard, Oncotype DX) with the commercial scale, payer relationships, and sales infrastructure that Nanostics would need to compete with at scale in cancer screening.

TypeBroad incumbent
Description

Guardant Health is a leading liquid biopsy company (Guardant360, Reveal) whose oncology liquid biopsy franchise overlaps with Nanostics' blood-based biomarker approach and represents a potential competitor or acquirer for adjacent indications.

TypeBroad incumbent
Description

Natera operates Signatera (MRD) and Prospera (transplant) blood-based tests using cfDNA analysis — overlapping with Nanostics in blood-based oncology diagnostics and representing a comparable commercial-stage molecular diagnostics peer.

TypeBroad incumbent
Description

Grail's Galleri multi-cancer early detection test and emerging single-cancer products compete for the same blood-based cancer screening thesis and payer attention that Nanostics targets in prostate cancer.

TypeBroad incumbent
Description

Philips is a major prostate MRI/imaging vendor whose prostate imaging pathway (PI-RADS, MRI fusion biopsy) is the dominant alternative to blood-based adjuncts like ClarityDX Prostate, especially in higher-resource urology practices.

TypeOthers
Description

Bio-Techne supplies proteomic biomarker assays and analytical tools used by diagnostics developers and academic prostate cancer labs, positioning it as an enabling tool/infrastructure provider adjacent to Nanostics' biomarker workflow.

TypeBroad incumbent
Description

Hologic is a diversified women's health and diagnostics company with a large commercial sales force into urology and primary care — the same channel Nanostics is targeting — and represents a potential strategic acquirer or distribution partner.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nanostics

Cancer Diagnosticsnanosticsdx.com

Nanostics Precision Health is an Edmonton-based diagnostic company that develops and commercializes ClarityDX Prostate, an AI-driven blood test that generates risk scores for aggressive prostate cancer to help patients and clinicians decide whether a biopsy is needed. The company sells the test directly to consumers across six Canadian provinces and through healthcare system partners, and is pursuing FDA approval for US market entry.

What Nanostics does

Nanostics Inc. (operating as Nanostics Precision Health) is a privately held Canadian diagnostic company headquartered in Edmonton, Alberta, that develops and commercializes the ClarityDX platform — an AI-driven blood-based diagnostic system for prostate cancer risk assessment. Its flagship product, ClarityDX Prostate, analyzes standard clinical inputs (age, total PSA, free PSA ratio, prostate volume, PI-RADS score, prior negative biopsy status, and DRE findings) through proprietary machine learning models to generate a risk score for aggressive prostate cancer (Grade Group ≥3). The platform offers four model variants (base, +DRE, +MRI, +DRE+MRI) that have demonstrated AUCs of 0.81–0.88 across multi-institutional validation and can reduce unnecessary biopsies by 47% while maintaining detection of over 94% of aggressive cancers. A complementary EV-Fingerprint test, which uses extracellular vesicle biomarkers analyzed via microflow cytometry combined with machine learning, is also in the company's pipeline.

Nanostics commercializes ClarityDX Prostate through a dual go-to-market approach: a direct-to-consumer e-commerce channel with provincial pricing ($300 CAD in Alberta, $500 CAD in British Columbia, undisclosed elsewhere), plus enterprise healthcare system partnerships anchored by a clinical laboratory relationship with Alberta Precision Laboratory. The test is currently available in six Canadian provinces (Alberta, British Columbia, Ontario, Quebec, Saskatchewan, and Yukon) and the company is pursuing FDA approval to enter the US market. The business is supported by grant and equity funding from Genome Canada, Genome Alberta, the University of Alberta Innovation Fund, NRC-IRAP, Alberta Innovates, Prostate Cancer Canada, Ride for Dad, and other regional partners, with the most recent disclosed round being a $2.79M Canadian Biotechnology Innovation and Commercialization Initiative round in June 2025.

The company operates with a small team of 1–10 employees led by CEO and founder Dr. John Lewis (Bird Dogs Chair of Translational Oncology at the University of Alberta), Co-Founder and COO Catalina Vasquez, CTO and Co-Founder Robert Paproski, CCO Colin Coros, and CSO Desmond Pink. The company originated from academic research at the University of Alberta and underwent a strategic pivot from its original nanotechnology focus to a machine learning diagnostic platform. Revenue is not publicly disclosed and the company remains in early commercialization, with growth signals concentrated in geographic expansion (FDA pathway), product extensions (EV-Fingerprint), and accumulating peer-reviewed scientific validation.

Nanostics firmographics

Firmographics
Name
Nanostics
Legal name
Nanostics Inc.
Website
https://nanosticsdx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Nanostics Precision Health is an Edmonton-based diagnostic company that develops and commercializes ClarityDX Prostate, an AI-driven blood test that generates risk scores for aggressive prostate cancer to help patients and clinicians decide whether a biopsy is needed. The company sells the test directly to consumers across six Canadian provinces and through healthcare system partners, and is pursuing FDA approval for US market entry.
Ownership category
akta.pro rank

Nanostics industry classification

Industry
Product category
Cancer Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Prostate cancer diagnostics
  • Blood-based biomarker assays
  • Machine learning diagnostics
  • Cancer risk prediction
  • Clinical laboratory services

Where Nanostics is headquartered

Location

Headquarters

HQ city
Edmonton
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Nanostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Test Sales: Revenue generated from direct sales of ClarityDX Prostate test to consumers and healthcare providers. Test is available for ordering online with pricing varying by province in Canada.
  2. Healthcare System Partnerships: Revenue potential through reimbursement agreements with provincial healthcare systems and adoption into clinical workflows.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goClarityDX Prostate Test - Alberta
Unit PricingPay-as-you-goClarityDX Prostate Test - British Columbia
Unit PricingPay-as-you-goClarityDX Prostate Test - Ontario
Unit PricingPay-as-you-goClarityDX Prostate Test - Quebec
Unit PricingPay-as-you-goClarityDX Prostate Test - Saskatchewan
Unit PricingPay-as-you-goClarityDX Prostate Test - Yukon

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Nanostics product offering

Product offering

Core offering

Nanostics develops and sells ClarityDX Prostate, a blood-based diagnostic test that uses proprietary machine learning algorithms to generate a risk score for aggressive prostate cancer (Grade Group ≥3) from standard clinical inputs (age, PSA, free PSA ratio, DRE, MRI findings) and blood-based biomarkers. The test is offered in four model variants (base, +DRE, +MRI, +DRE+MRI) and is processed at Nanostics' accredited clinical laboratory in Edmonton, with results used by urologists and primary care physicians to inform prostate biopsy decisions and reduce unnecessary invasive procedures.

Product overview

Nanostics offers the ClarityDX platform, an AI-powered diagnostic system for prostate cancer risk assessment. The core product is ClarityDX Prostate, a blood-based test that analyzes clinical features and blood-based biomarkers using machine learning to generate risk scores for aggressive prostate cancer. The platform offers four model variants: the base ClarityDX Prostate model, plus optional modules for Digital Rectal Exam (DRE) data and/or MRI data. Regional variants are available across Canadian provinces (Alberta, British Columbia, Ontario, Quebec, Saskatchewan, Yukon) with varying pricing. The test is designed as an adjunctive tool for men with elevated PSA results to help determine whether a prostate biopsy is necessary.

Differentiator

Problem solved

Functional benefit

Brands

  • ClarityDX: AI-powered diagnostic platform that analyzes clinical data to provide actionable decision support for next-step testing, applicable to a wide range of cancers and other diseases.
  • ClarityDX Prostate

Products and services

  • ClarityDX Prostate A blood-based diagnostic test that uses machine learning to analyze clinical features (age, total PSA, free PSA ratio, prostate volume from MRI, PI-RADS, prior negative biopsy status, DRE findings) and blood-based biomarkers to generate a calibrated risk score for aggressive prostate cancer (Grade Group ≥3). Designed as an adjunctive test for men with elevated PSA results to help determine whether a prostate biopsy is necessary; processed at Nanostics' accredited clinical laboratory in Edmonton. Achieves AUC of 0.81 in base form, with reductions of unnecessary biopsies by up to 47% while detecting over 94% of aggressive cancers.
  • ClarityDX Prostate +DRE Extended ClarityDX Prostate model variant incorporating Digital Rectal Exam (DRE) data in addition to clinical features and blood biomarkers to predict aggressive prostate cancer. Achieves AUC of 0.82 in multi-institutional validation across six institutions in Canada, the United States, and Europe.
  • ClarityDX Prostate +MRI Extended ClarityDX Prostate model variant incorporating MRI data (prostate volume and PI-RADS score) in addition to clinical features and blood biomarkers to predict aggressive prostate cancer. Achieves AUC of 0.87 without DRE and 0.88 with DRE in multi-institutional validation across six institutions in Canada, the United States, and Europe.
  • ClarityDX Prostate +DRE +MRI Extended ClarityDX Prostate model variant incorporating both Digital Rectal Exam (DRE) and MRI data (prostate volume, PI-RADS score) in addition to clinical features and blood biomarkers to predict aggressive prostate cancer. The combined-input configuration reaches the highest AUC in the published multi-institutional validation across six institutions in Canada, the United States, and Europe.

Quantifiable outcome

  • Reduces unnecessary biopsies by 47% while maintaining detection of over 94% of aggressive cancers
  • +4 more outcomes

Companies that use Nanostics

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Nanostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Nanostics partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • UCLA (University of California, Los Angeles)coreStrategic or Co-development PartnerClinical site for multi-institutional validation study of ClarityDX Prostate models. Provided patient data and clinical expertise for model development and validation.
  • Johns Hopkins UniversitycoreStrategic or Co-development PartnerClinical site for multi-institutional validation study contributing patient cohorts and clinical data for model validation across six institutions.
  • University of CalgarycoreStrategic or Co-development PartnerClinical site for multi-institutional validation study contributing patient data and urological expertise.
  • Thomayer University HospitalcoreStrategic or Co-development PartnerClinical site in Prague, Czech Republic for multi-institutional validation study, providing diverse patient population for model validation.
  • Chesapeake UrologycoreStrategic or Co-development PartnerClinical site for multi-institutional validation study contributing patient data from urology practice.
  • Alberta Precision LaboratorycoreStrategic or Co-development PartnerClinical laboratory partner shown in company partnerships section, involved in processing ClarityDX Prostate tests in Alberta.
  • Applied Pharmaceutical Innovation (API)minorStrategic or Co-development PartnerPartner organization supporting pharmaceutical innovation ecosystem in Alberta.
  • Scale Good FundminorStrategic or Co-development PartnerImpact fund supporting innovation and entrepreneurship in Edmonton/Alberta region.
  • Edmonton UnlimitedminorStrategic or Co-development PartnerEdmonton-based innovation ecosystem partner supporting startups and technology companies.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Nanostics competitors and assessment

Company assessment

Direct peers

  • MDxHealth: MDxHealth's SelectMDx is a urine-based molecular test that helps determine the risk of clinically significant prostate cancer prior to biopsy — directly competing with ClarityDX Prostate in the same urology decision-support workflow.
  • OPKO Health: OPKO markets the 4Kscore test, a blood-based prostate cancer risk assessment that, like ClarityDX Prostate, aims to reduce unnecessary biopsies by stratifying risk of aggressive disease in men with elevated PSA.
  • Veracyte: Veracyte's Decipher Prostate Genomic Classifier is a tissue-based genomic test for risk stratification in prostate cancer, addressing the same biopsy/treatment decision points that ClarityDX Prostate targets upstream of biopsy.

Broad incumbents

  • Exact Sciences: Exact Sciences is a major oncology diagnostics company (Cologuard, Oncotype DX) with the commercial scale, payer relationships, and sales infrastructure that Nanostics would need to compete with at scale in cancer screening.
  • Guardant Health: Guardant Health is a leading liquid biopsy company (Guardant360, Reveal) whose oncology liquid biopsy franchise overlaps with Nanostics' blood-based biomarker approach and represents a potential competitor or acquirer for adjacent indications.
  • Natera: Natera operates Signatera (MRD) and Prospera (transplant) blood-based tests using cfDNA analysis — overlapping with Nanostics in blood-based oncology diagnostics and representing a comparable commercial-stage molecular diagnostics peer.
  • Grail: Grail's Galleri multi-cancer early detection test and emerging single-cancer products compete for the same blood-based cancer screening thesis and payer attention that Nanostics targets in prostate cancer.
  • Philips: Philips is a major prostate MRI/imaging vendor whose prostate imaging pathway (PI-RADS, MRI fusion biopsy) is the dominant alternative to blood-based adjuncts like ClarityDX Prostate, especially in higher-resource urology practices.
  • Hologic: Hologic is a diversified women's health and diagnostics company with a large commercial sales force into urology and primary care — the same channel Nanostics is targeting — and represents a potential strategic acquirer or distribution partner.

Others

  • Bio-Techne: Bio-Techne supplies proteomic biomarker assays and analytical tools used by diagnostics developers and academic prostate cancer labs, positioning it as an enabling tool/infrastructure provider adjacent to Nanostics' biomarker workflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Nanostics social profiles

Digital presence

Nanostics compliance and trust

Trust signal

Compliance2 records

Nanostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nanostics leadership team

Management profile

Number of profiles

Profiles5 records

Nanostics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nanostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanostics

What does Nanostics do?

Nanostics develops and sells ClarityDX Prostate, a blood-based diagnostic test that uses proprietary machine learning algorithms to generate a risk score for aggressive prostate cancer (Grade Group ≥3) from standard clinical inputs (age, PSA, free PSA ratio, DRE, MRI findings) and blood-based biomarkers. The test is offered in four model variants (base, +DRE, +MRI, +DRE+MRI) and is processed at Nanostics' accredited clinical laboratory in Edmonton, with results used by urologists and primary care physicians to inform prostate biopsy decisions and reduce unnecessary invasive procedures.

Is Nanostics a public or private company?

Nanostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nanostics founded?

Nanostics was founded in 2017. It employs 11 to 50 people.

Where is Nanostics based?

Nanostics is headquartered in Edmonton, Canada, in the North America region.

How does Nanostics make money?

Two revenue lines are on record. Diagnostic Test Sales are the primary driver. The others are healthcare System Partnerships.

Who are Nanostics's main competitors?

Direct peers on record are MDxHealth, OPKO Health and Veracyte. Broad incumbents are Exact Sciences, Guardant Health, Natera, Grail, Philips and Hologic. Bio-Techne is listed as an others.

Does Nanostics have an API?

No public API is recorded for Nanostics.

What industry is Nanostics in?

Nanostics's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNanostics Announces Publication of a ClarityDX Prostate Study Validating New Algorithms with Improved Cancer Prediction that make MRI or DRE OptionalNanostics Inc. announced the publication of a peer-reviewed study in npj Digital Medicine validating its AI-driven ClarityDX Prostate models for predicting aggressive prostate cancer, developed and validated across six institutions in Canada, the United States, and Europe. The study demonstrated high accuracy with AUC values ranging from 0.81 to 0.88 across four model variants, with the base model achieving comparable performance to models incorporating MRI or DRE inputs. The research showed the technology could reduce unnecessary biopsies by 47% while maintaining detection of over 94% of aggressive cancers.NewswireNanostics Announces Publication of a ClarityDX Prostate Study Validating New Algorithms with Improved Cancer Prediction that make MRI or DRE OptionalNanostics published a study validating its ClarityDX Prostate AI models for predicting aggressive prostate cancer, with AUC values from 0.81 to 0.88. The models may reduce unnecessary biopsies by 47% while detecting over 94% of aggressive cancers, and MRI improves performance.Straits ResearchGlobal Prostate Cancer Diagnostics Market Size, ShareThe global prostate cancer diagnostics market was valued at USD 8.82 billion in 2024 and is projected to grow to USD 15.02 billion by 2033, registering a CAGR of 6.10% during the forecast period, driven by increasing prevalence of prostate cancer, aging populations, and technological advancements in diagnostic technologies. North America held the largest market share in 2024, while Europe is anticipated to exhibit the fastest CAGR of 12.5%, supported by rising disease incidence, awareness programs, and lower production costs. Among recent developments, DiaCarta, Inc. announced a strategic collaboration with OncoAssure Ltd in February 2024 to commercialize a prostate cancer recurrence risk test, and Nanostics launched its ClarityDX Prostate test in September 2023.PR NewswireMajor Investment from Genome Canada to Help Advance ClarityDX Prostate Adoption Across CanadaNanostics Inc. received funding from Genome Canada and Genome Alberta to integrate ClarityDX Prostate into Canadian prostate cancer screening. The project will assemble a clinical and economic evidence package to support reimbursement and public access, starting in Alberta.PR NewswireClinical study showing ClarityDX Prostate accurately predicts a patient's risk of having clinically significant prostate cancer published in Nature Digital MedicineNanostics Inc. announced the publication of a 3,448-patient international multi-center study validating its ClarityDX Prostate test in npj Digital Medicine (Nature family). The study demonstrated 95% sensitivity and 91% negative predictive value for detecting clinically significant prostate cancer (Grade Group 2+), showing the test to be three times more accurate than PSA screening alone, with the potential to reduce unnecessary prostate biopsies by up to 35%. The company is now making the test available to physicians and patients as an adjunctive screening tool for men with elevated PSA levels.Pulse 2.0Nanostics: Funding Raised From The University Of Alberta Innovation FundNanostics, a precision health company, announced it received an investment from the University of Alberta Innovation Fund to expand the adoption of its ClarityDX Prostate test in North America. This funding supports the expansion of the product pipeline, including the development of a new bladder cancer diagnostic test. The move aims to improve early detection of aggressive prostate cancer and reduce over-treatment associated with current screening methods.FinSMEsNanostics Receives Funding from the University of Alberta Innovation FundNanostics, an Edmonton-based precision health company, received funding from the University of Alberta Innovation Fund. The amount was not disclosed. The company will use the funds to promote adoption of its ClarityDX Prostate test in North America.NewswireNanostics Receives Funding from the University of Alberta Innovation Fund to Propel Adoption of the ClarityDX Prostate TestNanostics Inc. received an investment from the University of Alberta Innovation Fund to support the adoption of its ClarityDX Prostate test in North America. The funding will facilitate the expansion of access to the diagnostic test and support the development of a new bladder cancer diagnostic product. This initiative aims to address limitations in current prostate cancer screening methods by providing more accurate risk assessment for aggressive disease.PR NewswireNanostics Receives Funding from the University of Alberta Innovation Fund to Propel Adoption of the ClarityDX Prostate TestNanostics Inc. received an investment from the University of Alberta Innovation Fund to promote the adoption of its ClarityDX Prostate test in North America. This innovative blood test aims to improve prostate cancer screening by providing a risk score that supports informed decision-making for men suspected of having the disease. The funds will also assist in expanding the test's availability and developing additional diagnostic tests, including for bladder cancer.BioSpaceNanostics Receives Funding from the University of Alberta Innovation Fund to Propel Adoption of the ClarityDX Prostate TestNanostics Inc. received an investment from the University of Alberta Innovation Fund to support the adoption and expansion of its ClarityDX Prostate test in North America. The funding will be used to promote the blood test, which uses machine learning to assess prostate cancer risk, and to support the development of a new bladder cancer diagnostic test. This initiative aims to address the limitations of current PSA screening methods by providing more accurate detection of aggressive prostate cancer.